CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Pirtobrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06180980
NCT06180980Phase 1Completed
CompareCT.gov

A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Pirtobrutinib (LOXO-305) in Healthy Subjects

Eli Lilly and Company·interventional·Posted Dec 26, 2023·Updated Mar 7, 2025

In Brief

A Phase 1 clinical trial evaluating Pirtobrutinib for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53 days (screening through follow-up call).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedDec 26, 2023
Enrollment StartJan 4, 2021
Primary CompletionMar 8, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.5 years ago

Interventions

Pirtobrutinibdrug

Administered orally.